Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
SMMT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $13.70B
- EPS (TTM)
- -$1.11
- Dividend yield
- None
- 52-week range
- 12.07 – 29.23
- Day range
- 16.80 – 17.64
- Volume / Avg
- 6.17M / 5.82M
- Beta
- —
- Shares outstanding
- 797.75M
- Next earnings
- Oct 19, 2026
52-week range
SMMT stock today
Shares of Summit Therapeutics (SMMT) finished lower on Oct 8 at $17.17, a drop of 4.35% or $0.78 per share, versus the S&P 500's 0.47% decline. Shares are 41.3% below their 52-week high of $29.23, set on Apr 21, 2026 and 42.3% above the 52-week low of $12.07, in the middle of the past year's range. SMMT is down 1.8% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 26.4%.
Summit Therapeutics has posted a net loss over the last twelve months (EPS of -$1.11), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Oct 19; analysts expect EPS of -$0.28.
Summary generated from market data by MetaCap's automated system. Methodology
About Summit Therapeutics
Company profileSummit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Robert W. Duggan
- Headquarters
- Miami, FL
- Employees
- 265
- IPO year
- 2015
- Website
- smmttx.com
Financial highlights
Full financialsSummit Therapeutics reported a net loss of $1.08 billion, compared with a loss of $221.3 million a year earlier. Diluted earnings per share came in at -$1.44.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $705.00K | $1.81M |
| Growth | — | — | -100.00% | -61.03% | +110.35% |
| Net income | $-1.08B | $-221.31M | $-614.93M | $-78.78M | $-88.60M |
| EPS (diluted) | $-1.44 | $-0.31 | $-0.99 | $-0.41 | $-0.67 |
Analyst forecast
ForecastConsensus (17 analysts)
buy
Avg. price target
$29.75+73.27%
- Strong buy 1
- Buy 10
- Hold 6
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 19, 2026
- EPS estimate
- $-0.28
- Last reported (Q2 2026)
- Jul 23, 2026
- EPS actual vs est.
- $-0.28 vs —
SMMT news
All SMMT news- SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway CombosNasdaqSMMT, AZN, PFE
- Summit Therapeutics Secures $2B Strategic Investment From AstraZenecaNasdaqAZN, SMMT
- Daiichi Sankyo, AstraZeneca, Summit Partner On Datroway- Ivonescimab Cancer StudiesNasdaqAZN, SMMT
- Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus IvonescimabNasdaqAZN, SMMT
- Summit Shares Jump on $2B Strategic Investment From AstraZenecaNasdaqSMMT, AZN, PFE
- AstraZeneca Invests $2 Billion In Summit, Expands Cancer Drug Collaboration; Stock UpNasdaqAZN, SMMT
- RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic CancerNasdaqRVMD, BMY, SMMT, TNGX
Summit Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| JAZZJazz Pharmaceuticals plc | 222.45 | -3.78% | $14.44B | vs SMMT |
| CORTCorcept Therapeutics Incorporated | 118.54 | -0.89% | $12.81B | vs SMMT |
| ASNDAscendis Pharma A/S | 222.69 | -2.50% | $14.65B | vs SMMT |
| BBIOBridgeBio Pharma Inc. | 65.04 | -2.20% | $12.71B | vs SMMT |
| ELANElanco Animal Health Incorporated | 22.54 | +0.81% | $11.26B | vs SMMT |
| MDGLMadrigal Pharmaceuticals Inc. | 476.91 | -2.22% | $11.02B | vs SMMT |
| BMRNBioMarin Pharmaceutical Inc. | 54.89 | -0.56% | $10.63B | vs SMMT |
| RDYDr. Reddy's Laboratories Ltd | 12.20 | -0.57% | $10.16B | vs SMMT |
Indexes, lists and sector
Summit Therapeutics stock FAQ
What is Summit Therapeutics's stock price today?
SMMT last traded at $17.17 as of Oct 8, 4:00 PM EDT, down 4.35% on the day. Prices are delayed at least 15 minutes.
When is Summit Therapeutics's next earnings date?
Summit Therapeutics is expected to report earnings on Monday, October 19, 2026. Analysts expect EPS of $-0.28.
Who is Summit Therapeutics's CEO?
Mr. Robert W. Duggan is the chief executive officer of Summit Therapeutics Inc., which has about 265 employees.
What is the SMMT 52-week high?
The 52-week high for SMMT is $29.23 and the 52-week low is $12.07. The stock is currently 41.3% below its high.